Loading
This consensus proposed a uniform way of classifying neuroendocrine neoplasms at every body site, separating well-differentiated neuroendocrine tumours (graded 1 to 3) from poorly differentiated neuroendocrine carcinomas, which became the basis of the WHO 2019 and 2022 classifications.
Expert consensus from the International Agency for Research on Cancer and WHO proposing that neuroendocrine neoplasms across organs be divided into well-differentiated neuroendocrine tumours graded 1 to 3 by proliferation and poorly differentiated small- and large-cell neuroendocrine carcinomas, with mixed neuroendocrine-non-neuroendocrine neoplasms as a third family.
The grade 3 neuroendocrine tumour category, treated differently from neuroendocrine carcinoma, exists because of this framework.
Shares Grade 3 well-differentiated neuroendocrine tumour, Extrapulmonary neuroendocrine carcinoma.
Shares Grade 3 well-differentiated neuroendocrine tumour, Extrapulmonary neuroendocrine carcinoma.
Shares Grade 3 well-differentiated neuroendocrine tumour, Extrapulmonary neuroendocrine carcinoma.
Shares Grade 3 well-differentiated neuroendocrine tumour, Extrapulmonary neuroendocrine carcinoma.
Shares Grade 3 well-differentiated neuroendocrine tumour, Extrapulmonary neuroendocrine carcinoma.
Shares Grade 3 well-differentiated neuroendocrine tumour, Extrapulmonary neuroendocrine carcinoma.